Savara(US:SVRA) Globenewswire·2025-10-06 18:25Core Points - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application (BLA) during the class period from March 7, 2024, to May 23, 2025 [2][8] - The lawsuit claims that the FDA was unlikely to approve the MOLBREEVI BLA in its current form due to insufficient information, which could lead to delays in regulatory approval and the need for Savara to raise additional capital [8] Allegation Details - The complaint alleges that Savara did not disclose that the MOLBREEVI BLA lacked sufficient information regarding its chemistry, manufacturing, and controls [8] - On May 27, 2025, Savara announced it received a refusal to file (RTF) letter from the FDA, causing its stock price to drop by $0.90, or 31.69%, closing at $1.94 per share [8] Next Steps - Investors who purchased Savara shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [4] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 7, 2025 [2] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5] - The firm has offices in New York, California, and South Carolina, and provides services in commercial and securities litigation [5]